Skip to content 
Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreement with the University of Jaén, to undertakes the research activities for the POP1 Program and the University of Granada to develop a synthetic recombinant version of PRP. Propanc Biopharma, Inc. was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. The company was incorporated in 2007 and is based in Camberwell, Australia. more
| Time Frame | PPCB | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | -12.25% | 0.81% | 0.49% |
| 1-Month Return | -32.16% | 1.2% | 1.02% |
| 3-Month Return | -76.43% | 3.24% | 3.34% |
| 6-Month Return | -94.48% | 14.99% | 7.04% |
| 1-Year Return | -97.72% | 7.42% | 11.68% |
| 3-Year Return | -100% | 20.71% | 71.63% |
| 5-Year Return | -100% | 37.45% | 75.56% |
| 10-Year Return | -100% | 138.53% | 257.55% |
| Jun '21 | Jun '22 | Jun '23 | Jun '24 | Jun '25 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | - | - | - | - | - | [{"date":"2021-06-30","value":"-","profit":true},{"date":"2022-06-30","value":"-","profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":"-","profit":true},{"date":"2025-06-30","value":"-","profit":true}] |
| Cost of Revenue | 28.11K | 5.67K | 17.76K | 21.66K | - | [{"date":"2021-06-30","value":100,"profit":true},{"date":"2022-06-30","value":20.17,"profit":true},{"date":"2023-06-30","value":63.18,"profit":true},{"date":"2024-06-30","value":77.03,"profit":true},{"date":"2025-06-30","value":"-","profit":true}] |
| Gross Profit | (28.11K) | (5.67K) | (17.76K) | (21.66K) | - | [{"date":"2021-06-30","value":-2811200,"profit":false},{"date":"2022-06-30","value":-567100,"profit":false},{"date":"2023-06-30","value":-1776000,"profit":false},{"date":"2024-06-30","value":-2165600,"profit":false},{"date":"2025-06-30","value":"-","profit":true}] |
| Gross Margin | - | - | - | - | - | [{"date":"2021-06-30","value":"-","profit":true},{"date":"2022-06-30","value":"-","profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":"-","profit":true},{"date":"2025-06-30","value":"-","profit":true}] |
| Operating Expenses | 1.81M | 1.99M | 1.76M | 1.51M | 57.28M | [{"date":"2021-06-30","value":3.16,"profit":true},{"date":"2022-06-30","value":3.47,"profit":true},{"date":"2023-06-30","value":3.07,"profit":true},{"date":"2024-06-30","value":2.64,"profit":true},{"date":"2025-06-30","value":100,"profit":true}] |
| Operating Income | (1.81M) | (1.99M) | (1.78M) | (1.54M) | (57.28M) | [{"date":"2021-06-30","value":-181200000,"profit":false},{"date":"2022-06-30","value":-199100000,"profit":false},{"date":"2023-06-30","value":-177700000,"profit":false},{"date":"2024-06-30","value":-153600000,"profit":false},{"date":"2025-06-30","value":-5727813100,"profit":false}] |
| Total Non-Operating Income/Expense | (776.46K) | (1.29M) | (1.55M) | (1.08M) | (2.21M) | [{"date":"2021-06-30","value":-77645600,"profit":false},{"date":"2022-06-30","value":-128518500,"profit":false},{"date":"2023-06-30","value":-154678500,"profit":false},{"date":"2024-06-30","value":-107978100,"profit":false},{"date":"2025-06-30","value":-220891700,"profit":false}] |
| Pre-Tax Income | (2.14M) | (2.71M) | (2.79M) | (1.95M) | (58.92M) | [{"date":"2021-06-30","value":-213900000,"profit":false},{"date":"2022-06-30","value":-271300000,"profit":false},{"date":"2023-06-30","value":-279000000,"profit":false},{"date":"2024-06-30","value":-195000000,"profit":false},{"date":"2025-06-30","value":-5892330000,"profit":false}] |
| Income Taxes | (113.00K) | (54.98K) | (130.00K) | (129.00K) | - | [{"date":"2021-06-30","value":-11300000,"profit":false},{"date":"2022-06-30","value":-5497700,"profit":false},{"date":"2023-06-30","value":-13000000,"profit":false},{"date":"2024-06-30","value":-12900000,"profit":false},{"date":"2025-06-30","value":"-","profit":true}] |
| Income After Taxes | (2.03M) | (2.66M) | (2.66M) | (1.82M) | - | [{"date":"2021-06-30","value":-202600000,"profit":false},{"date":"2022-06-30","value":-265802300,"profit":false},{"date":"2023-06-30","value":-266000000,"profit":false},{"date":"2024-06-30","value":-182100000,"profit":false},{"date":"2025-06-30","value":"-","profit":true}] |
| Income From Continuous Operations | (2.03M) | (2.66M) | (2.66M) | (1.82M) | (58.92M) | [{"date":"2021-06-30","value":-202594700,"profit":false},{"date":"2022-06-30","value":-265808700,"profit":false},{"date":"2023-06-30","value":-266056600,"profit":false},{"date":"2024-06-30","value":-182052800,"profit":false},{"date":"2025-06-30","value":-5892330000,"profit":false}] |
| Income From Discontinued Operations | - | - | - | - | - | [{"date":"2021-06-30","value":"-","profit":true},{"date":"2022-06-30","value":"-","profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":"-","profit":true},{"date":"2025-06-30","value":"-","profit":true}] |
| Net Income | (2.03M) | (2.66M) | (2.66M) | (1.82M) | (58.92M) | [{"date":"2021-06-30","value":-202600000,"profit":false},{"date":"2022-06-30","value":-265800000,"profit":false},{"date":"2023-06-30","value":-266100000,"profit":false},{"date":"2024-06-30","value":-182100000,"profit":false},{"date":"2025-06-30","value":-5892330000,"profit":false}] |
| EPS (Diluted) | (0.67) | (0.06) | (0.14) | (45.01) | (116.47) | [{"date":"2021-06-30","value":-67,"profit":false},{"date":"2022-06-30","value":-6,"profit":false},{"date":"2023-06-30","value":-13.66,"profit":false},{"date":"2024-06-30","value":-4500.54,"profit":false},{"date":"2025-06-30","value":-11646.72,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
| PPCB | |
|---|---|
| Cash Ratio | 0.15 |
| Current Ratio | 2.13 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| PPCB | |
|---|---|
| ROA (LTM) | -427.27% |
| ROE (LTM) | -1236.83% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| PPCB | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.24 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.69 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| PPCB | |
|---|---|
| Trailing PE | 0.00 |
| Forward PE | NM |
| P/S (TTM) | 0.00 |
| P/B | 0.23 |
| Price/FCF | NM |
| EV/R | 0.00 |
| EV/Ebitda | NM |
| PEG | NM |
Propanc Biopharma, Inc. Common Stock (PPCB) share price today is $0.191
Yes, Indians can buy shares of Propanc Biopharma, Inc. Common Stock (PPCB) on Vested. To buy
Yes, you can purchase fractional shares of Propanc Biopharma, Inc. Common Stock (PPCB) via the Vested app. You can start investing in Propanc Biopharma, Inc. Common Stock (PPCB) with a minimum investment of $1.
You can invest in shares of Propanc Biopharma, Inc. Common Stock (PPCB) via Vested in three simple steps:
The 52-week high price of Propanc Biopharma, Inc. Common Stock (PPCB) is $11. The 52-week low price of Propanc Biopharma, Inc. Common Stock (PPCB) is $0.16.
The price-to-earnings (P/E) ratio of Propanc Biopharma, Inc. Common Stock (PPCB) is 0.0008
The price-to-book (P/B) ratio of Propanc Biopharma, Inc. Common Stock (PPCB) is 0.23
The dividend yield of Propanc Biopharma, Inc. Common Stock (PPCB) is 0.00%
The market capitalization of Propanc Biopharma, Inc. Common Stock (PPCB) is $3.06M
The stock symbol (or ticker) of Propanc Biopharma, Inc. Common Stock is PPCB
Consider the share price of Propanc Biopharma, Inc. Common Stock as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Propanc Biopharma, Inc. Common Stock has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Propanc Biopharma, Inc. Common Stock shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Propanc Biopharma, Inc. Common Stock stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Propanc Biopharma, Inc. Common Stock and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Propanc Biopharma, Inc. Common Stock stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
